NCT02922166Unknown1 期
Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Azevan Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2017年2月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Change in startle reflex between SRX246 and Placebo
研究概览
简要总结
To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.
详细描述
The study will use a double-blind, cross-over design in which each subject will receive placebo and SRX246 for 5-7 days before testing (given in counter-balanced order). The study will examine the effect of the drug on the potentiation of startle using a well-established paradigm that involves anticipation of no-shock, predictable shock, and unpredictable shock. Drug effects on emotion recognition will also be explored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female volunteers, ages 21-50, inclusive.
- •Subjects able to give their consent and have signed informed consent forms indicating that they understand the purpose and procedures of the study and are willing to participate in the study procedures and restrictions.
- •Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).
排除标准
- •Non-English speakers
- •Current or history of Axis I psychiatric disorder(s) as identified with the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np) and clinical evaluation.
- •Active or history of active suicidal ideation.
- •Lifetime alcohol or drug dependence according to the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np).
- •All prescription and non-prescription medications and herbal remedies are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and until at least 7 days or 5 half-lives (whichever is longer) after last dose of study medication, except hormonal contraceptives in females.
- •Clear evidence of a first-degree relative with history of psychosis, bipolar disorder or major depression as determined by the family history method; specifically, participant will know diagnosis or treatment in order to confirm presence of disorder.
- •Subject is currently participating in another clinical trial in which (s)he is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month.
- •Current evidence or history of significant medical illness or organic brain impairment, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), diabetes insipidus (DI), stroke, epilepsy, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere with the action, absorption, distribution, metabolism, or excretion of SRX246, or influence psychophysiological responses.
- •Current evidence of median nerve entrapment or carpal tunnel syndrome.
- •Any laboratory abnormality that in the investigators' judgment is considered to be clinically significant (ECG, TSH, LFT, etc.).
- •Abnormal urine specific gravity (below 1.00 or above 1.03) as documented by urine sample refractometry.
- •Subject who has resting blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
- •Subject who has resting pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
- •Consumption of illicit substances or positive urine toxicology screen throughout the study.
- •Pregnancy, lactating/breastfeeding, or positive pregnancy test.
- •A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to SRX246, or allergy to gelatin.
- •Lack of measurable startle response (3 times the baseline EMG activity) for all 9 startles used during the habituation visit.
- •Subjects who would be noncompliant with the visit schedule or study procedures. Possible noncompliance may include planned vacations or planned hospitalizations during the study.
- •For women who are able to get pregnant and men who are able to father a child, unwillingness to use at least two effective birth control methods for 15 days prior to the time they enroll in the study, and for 15 days after their last exposure to the study drug. Effective methods of contraception for this study include:
- •hormonal contraception (birth control pills, injected hormones or vaginal ring),
- •intrauterine device,
- •barrier methods (condom or diaphragm) combined with spermicide, and
- •surgical sterilization (hysterectomy, tubal ligation, or vasectomy).
- •Employee of NIMH or an immediate family member who is a NIMH employee
研究组 & 干预措施
SRX246
Experimental
SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
干预措施: SRX246 (Drug)
Placebo
Placebo Comparator
Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
干预措施: Placebo (Drug)
结局指标
主要结局
Change in startle reflex between SRX246 and Placebo
时间窗: up to 7 days
Subjects will be exposed to none (N), predictable (P) and unpredictable (U) acoustic and electric shocks.
次要结局
- Change in emotional expression recognition between SRX246 and Placebo(up to 7 days)
- Change in State Anxiety Scale between SRX246 and Placebo(up to 7 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of SRX246 Capsules in Healthy Adult VolunteersHealthyNCT00910455Azevan Pharmaceuticals49
已完成
不适用
Psychopharmacology of Fear-Potentiated Startle in HumansHealthyNCT00044096National Institute of Mental Health (NIMH)225
已完成
2 期
Treatment Of Patients With Social Anxiety DisorderSocial PhobiaNCT00397722GlaxoSmithKline299
已完成
不适用
A Controlled Trial of Losartan in Posttraumatic Stress DisorderPosttraumatic Stress DisorderNCT02709018University of California, San Diego149
已完成
1 期
Safety Study of SRX251 Capsules in Healthy Female VolunteersHealthyNCT00461370Azevan Pharmaceuticals77